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Abstract: Pramipexole is a non-ergot dopamine agonist shown to be efﬁ  cacious in the treatment 
of Parkinson’s disease (PD). This review addresses the literature concerning pramipexole’s 
efﬁ  cacy in treating motor and non-motor symptoms in PD, its impact on the development of 
dyskinesias and response ﬂ  uctuations, the issue of neuroprotection, and the risk for developing 
adverse events such as increased somnolence, attacks of sudden onset of sleep, cardiac valvu-
lopathy and impulse control disturbances.
Keywords: pramipexole, Parkinson’s disease, efﬁ  cacy, adverse events
Parkinson’s disease
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, 
affecting almost 1% of the population above the age of 60 years. Its early manifestation 
is parkinsonism, a progressive impairment of movement control including rigidity, 
rest tremor, and bradykinesia, while postural instability is a later feature. Non-motor 
symptoms caused by autonomic disturbances, dysregulation of mood and sleep, changes 
in cognition and behavior, are present throughout the course of the disease and may 
become, in advanced stages, the most important cause of disability.
Introduction to the dopaminergic treatment
of Parkinson’s disease
Levodopa
The most effective and widely used drug in PD is still levodopa, metabolized to dopa-
mine in the brain. During the early phases, motor symptoms in PD respond generally 
well to levodopa treatment. With advancing disease, treatment related complications 
such as response ﬂ  uctuations (“wearing off ”, “on-off”), motor disturbances (dyskinesias, 
“off” dystonia), neuropsychiatric side effects (hallucinations, delusions, confusion), and 
diminished response to levodopa, emerge as major causes of disability.
Dopamine agonists
The levodopa related complications prompted the development of alternative antipar-
kinsonian drugs, such as cathecolamine-O-methyl-transferase inhibitors, monoamine-
oxidase-B inhibitors, and the synthetic dopamine agonists (DA). The DA present 
several advantages over levodopa such as direct stimulation of striatal dopaminergic 
neurons, longer half-life providing a more continuous stimulation at the dopamine 
receptors, lack of oxidative metabolites, more reliable absorption and transport.
DA have been shown to be effective in PD, both as monotherapy and as adjuvants 
to levodopa (Cotzias et al 1975; Kartzinel et al 1976; Libman et al 1987; Ahlskog et al 
1994; Rinne et al 1997; Brooks et al 1998;  Parkinson Study Group 2000; Poewe and 
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Pramipexole in Parkinson’s disease
This review will present the DA pramipexole in the treatment 
of PD, focusing on the latest developments.
Pharmacodynamics
Pramipexole is a non-ergotamine full agonist at the D2 
subfamily of dopamine receptors, with higher selectivity 
for D3 than for D2 and D4 dopamine receptors (Mierau and 
Schingnitz 1992; Svensson et al 1994; Mierau 1995; Mierau 
et al 1995; Bennett and Piercey 1999). Thereby, pramipex-
ole is able to simultaneously excite the direct striatopallidal 
pathway (by D3 stimulation) and to inhibit the indirect 
striatopallidal pathway (by D2 stimulation), alleviating PD 
symptoms by mimicking dopamine’s effects in the striatum. 
Since the D3 receptors enjoy greatest predominance in the 
limbic system (Bouthenet et al 1991), pramipexole has the 
theoretical potential to also have an impact on psychiatric 
symptoms in PD (Bennett and Piercey 1999). In addition, 
pramipexole has a very low afﬁ  nity for 5-HT2A, 5-HT2B, 
and D1 receptors, partly explaining its beneﬁ  cial effects 
in the context of cardiac valvulopathy and dyskinesias, as 
discussed later.
Pharmacokinetics
Pramipexole has an absolute oral bioavailability greater 
than 90%, indicating good absorption and little ﬁ  rst pass 
metabolism. It exhibits linear pharmacokinetics and less 
than 20% is protein bound; more than 90% of the absorbed 
dose is eliminated unchanged and almost exclusively by the 
kidneys, motivating a dose reduction with low creatinine 
clearance. Its elimination half-life is 8 hours in young, healthy 
volunteers (Häselbarth 1994a, b; Wright et al 1997; Bennett 
and Piercey 1999).
In men and postmenopausal women with PD, gender 
had no impact on the pharmacokinetics of pramipexole, 
and pramipexole did not alter levodopa’s bioavailability 
(Kompoliti et al 2002).
In contrast to other DA, pramipexole has been found 
to exert no strong cytochrome P 450 inhibition in vitro, 
minimizing the risk for drug-drug interactions (Wynalda and 
Wienkers 1997).
Clinical efﬁ  cacy
Monotherapy in early Parkinson’s disease
Summary of previous results: The safety and efﬁ  cacy of 
pramipexole as monotherapy in early PD were originally 
evaluated in 2 placebo-controlled clinical trials enrolling 
599 PD subjects (Parkinson Study Group 1997; Shannon 
et al 1997). In addition, the Comparison of the Agonist 
Pramipexole with Levodopa on Motor Complications of 
PD (CALM-PD) study, conducted by the Parkinson Study 
Group (PSG), investigated initial treatment with pramipex-
ole vs initial treatment with levodopa in 301 patients with 
early PD, requiring dopaminergic therapy. The subjects 
were randomly assigned to receive 1.5 mg pramipexole or 
300 mg levodopa daily. The two treatment groups were of 
equal size. After the ﬁ  rst 10 weeks of treatment, open-label 
levodopa (and during the last year of the study also other 
antiparkinsonian medication) could be added as needed, for 
better symptom control (Parkinson Study Group 2000). The 
CALM-PD study design and the subsequent long follow up 
(up to 58 months), generated a wealth of data regarding the 
effects of pramipexole on a variety of PD features.
The combined results of these three pivotal studies showed 
that pramipexole, started at low initial doses and up-titrated 
weekly, was effective and well tolerated in mild to moderate 
PD. No differences in effectiveness based on age or gender 
were detected, and no dose-response relationship could be 
demonstrated. Thus, doses of 1.5 mg, 3 mg, 4.5 mg, and 
6 mg/day did provide similar signiﬁ  cant beneﬁ  t in reducing 
PD signs and symptoms compared with placebo. How-
ever, several side effects were dose related. On the Uniﬁ  ed 
Parkinson’s Disease Rating Scale (UPDRS) (Lang 1989) 
signiﬁ  cant improvement from baseline could be seen in both 
section II (around 2 points), and section III (around 5 points), 
compared with placebo (0.6 points on both sections).
New studies: The 4-year results of the CALM-PD study 
showed that, after 4 years, initial treatment with pramipexole 
resulted in a signiﬁ  cant reduction of the risk for developing 
treatment ﬂ  uctuations and dyskinesias but in a higher risk 
for freezing, vs initial treatment with levodopa. On the other 
side, a greater improvement in the total UPDRS score was 
seen in the levodopa group vs the pramipexole group (2 ± 
15.4 points vs –3.2 ± 17.3 points). More patients in the prami-
pexole group needed at 4 years open-label levodopa vs the 
levodopa group (72% vs 59%) but the mean daily levodopa 
dose was lower in the pramipexole group (434 ± 498 mg/day 
vs 702 ± 461 mg/day). More pramipexole patients withdrew 
prior to the ﬁ  nal follow-up visit than levodopa patients (45% 
vs 33 %) due to side-effects (Holloway et al 2004).
Adjuvant therapy in advanced Parkinson’s disease
Summary of previous results: Several clinical trials exam-
ined the medium and long term efﬁ  cacy of pramipexole at a 
maximal dosage of 4.5 mg daily, as an adjuvant to levodopa 
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showed that pramipexole was well tolerated, associated with 
a reduction in daily L-dopa usage, and in daily “off” time, 
together with improvement in several parkinsonism and dis-
ability scorings (Lieberman et al 1997; Bennett and Piercey 
1999; Pinter et al 1999, 2000; Weiner et al 2001).
New studies: Möller et al reported 2005 on 354 levodopa-
treated PD patients with motor ﬂ  uctuations. A ﬁ  rst, double-
blind, placebo controlled phase of 32 weeks was followed by 
an open-label phase with a maximum duration of 57 months. 
Pramipexole was administered t.i.d. at a total daily dosage 
varying between 0.375 and 4.5 mg. The effect emerged 
at a daily dose of 0.75 mg. The levodopa dosage could be 
decreased in 39% of the pramipexole treated patients vs in 
12.8% of the placebo group. Pramipexole as an adjuvant 
therapy was found to be superior to placebo and effective 
at reducing UPDRS sum scores of parts II and III by 30%, 
and “off time” by 2.5 hours/day. Improvement was also seen 
on UPDRS part I through the items motivation/initiative 
and depression, but not intellectual impairment and thought 
disorder. Overall, pramipexole had a better anti tremor effect 
than placebo (change –2.5 and –0.5 respectively on the sum 
of UPDRS tremor-related items). Tremor was considered 
prominent when the baseline sum score of UPDRS III tremor-
related items was at least 8 (6 if unilateral tremor) or the 
relative contribution of tremor items to the total UPDRS II and 
III score was 20%. Patients with prominent resting tremor 
beneﬁ  ted more from pramipexole than from placebo. Thus, 
the mean (SD) decrease in the total tremor score in the high 
tremor score group was 8 (4.2) for pramipexole compared with 
3.7 (5.7) for placebo. The prevalence of somnolence was low 
(1.7% in the pramipexole group vs 2.2 in the placebo group), 
but this symptom was not speciﬁ  cally asked for, just recorded 
if spontaneously reported. There were more dyskinesias and 
visual hallucinations in the pramipexole group vs the placebo 
group (30% vs 8.7%, and 11.1% vs 4.4% respectively). During 
the double-blind phase, totally 27% of all patients (17.8% in 
the pramipexole group and 36.1% in the placebo group) had 
an adverse event that led to the discontinuation of the study 
medication, most frequently due to aggravated parkinsonism. 
During the open-label phase, 23.7% of all subjects had an 
adverse event that led to discontinuation of study medication, 
most often aggravated parkinsonism, visual hallucinations, 
and dyskinesias. Pramipexole’s long-term efficacy and 
tolerability were good (Moller et al 2005).
Two studies examined pramipexole’s efﬁ  cacy in other 
ethnical groups than Caucasians. The ﬁ  rst, a 15-week-long, 
randomized, double-blind, placebo-controlled, parallel-group 
study, was conducted in Hong Kong and Taiwan in 150 
untreated and levodopa-treated Chinese patients with both 
early and advanced PD (Wong et al 2003). Pramipexole, 
both as monotherapy and as adjuvant to levodopa, was found 
to be more effective than placebo for symptom reduction 
measured with UPDRS Part I, Part III, and Parts I plus III. 
Pramipexole addition to levodopa led to a decrease in the 
number of “off” hours per day from 7.07 to 6.15 hours/day. 
In the placebo group the “off” time increased from 5.59 to 
6.87 hours/day. Slightly more adverse events were reported 
overall for pramipexole treated patients (86%) compared 
with the placebo group (71%), with the largest differences 
for constipation, nausea, dry mouth, dyskinesias, somnolence 
and hallucinations. Interestingly, more tremor was reported 
in the placebo group (11.7%) compared with the pramipexole 
group (1.4%), possibly indicating a more speciﬁ  c antitremor 
effect for pramipexole.
The results of the second study were published recently. 
In a 10 weeks long, double-blind, randomized, placebo-
controlled trial, pramipexole was administrated as an 
adjuvant therapy to 144 levodopa-treated PD patients of 
African American, Asian, and Hispanic heritage (Parkinson 
Study Group 2007). Overall, pramipexole was found to 
have a similar efﬁ  cacy in all ethnical groups, and of the 
same magnitude as shown in former trials on primarily non-
Hispanic whites. African Americans showed a statistically 
signiﬁ  cant improvement in tremor measured by UPDRS 
part 3 tremor subscales. The overall tolerability and safety 
were also similar across the ethnical lines, but with different 
proﬁ  les in the different groups. More patients of Asian 
heritage reported asthenia compared with African Americans 
and Hispanics, while confusion was more frequent in the 
African heritage group. Hallucinations and insomnia were 
more common with pramipexole than with placebo. No sleep 
attacks were reported. Premature withdrawals occurred 3 
times more frequently in persons of African heritage than in 
Asians, usually due to comorbid illnesses. These differences 
were not statistically signiﬁ  cant but may indicate the need 
of more research in this ﬁ  eld. A pharmacokinetic substudy 
on 40 patients did not show any differences in the pharma-
cokinetic proﬁ  le among the ethnic groups.
Comparative studies
Rotigotine: In 506 subjects with advanced PD already treated 
with levodopa and other antiparkinsonian drugs, pramipexole 
was compared with rotigotine patch and placebo, as adju-
vants. Primary efﬁ  cacy variables were absolute change in 
total hours “off ” from baseline to end of study, as recorded 
by patients on home diaries, and responder rate, deﬁ  ned as Neuropsychiatric Disease and Treatment 2008:4(2) 340
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the proportion of patients with a 30% or more reduction in 
absolute off time per day. Both active therapies showed simi-
lar efﬁ  cacy in respect to both primary and secondary response 
parameters, and were superior to placebo. Responder rates 
and reduction in off-time were in absolute numbers some-
what higher for pramipexole, but not enough to show any 
statistically signiﬁ  cance. Both pramipexole and rotigotine 
showed good tolerability, with more reports of hallucina-
tions, dyskinesias and dizziness in the pramipexole group, 
and more reports of nausea and application site reactions in 
the rotigotine group (Poewe et al 2007).
Bromocriptine: Pramipexole was compared with bro-
mocriptine and placebo as adjuvant therapy in 325 patients 
with advanced PD. The primary end points were the change 
from baseline to study termination on UPDRS parts II and 
III. The magnitude of the observed changes on the primary 
endpoints was larger, the response came earlier, and the 
improvement from baseline to each subsequent visit was 
greater in the pramipexole group compared with bromocrip-
tine, throughout the treatment. Statistically, the two treat-
ment groups were similar, presumably due to an insufﬁ  cient 
number of patients and low power. Both active treatments 
showed the same rate of responders and the rate of adverse 
events was similar for all 3 groups. Overall, pramipexole 
was shown to be clearly superior to placebo and not inferior 
to bromocriptine (Mizuno et al 2003).
Guttman et al compared adjuvant therapy with pramipex-
ole and placebo in PD patients with a declining response to 
levodopa, including a bromocriptine group for comparison 
with placebo. The primary end points were UPDRS parts II 
and III. They found no differences in efﬁ  cacy and adverse 
events between pramipexole and bromocriptine but the study 
was not powered for detecting any. Both DA were superior 
to placebo (Guttman 1997).
Pergolide: Rektorová et al found no signiﬁ  cant differ-
ences between pramipexole and pergolide as add-on therapies 
to levodopa in advanced PD patients with depression, as 
measured on UPDRS scales (Rektorova et al 2003).
In an open label study including 25 patients, Hanna et al 
found no signiﬁ  cant difference in the efﬁ  cacy of pramipexole 
vs pergolide as adjuvant therapies in mild to moderate PD, 
although there was a slight trend in favour or pramipexole 
(Hanna et al 2001).
Mixed: Goetz et al investigated slow (over 8 weeks) vs 
rapid (over 1 day) switch from bromocriptine/pergolide to 
pramipexole in 16 PD patients on stable levodopa therapy. The 
primary outcome was the time required to achieve a UPDRS 
motor score superior to baseline without increased side effects. 
The conversion rate to pramipexole was 1:1 for pergolide 
and 1:10 for bromocriptine. They found that a rapid titration 
based upon an equivalency dose calculation was preferable. 
Pramipexole was superior to both pergolide and bromocriptine 
in respect to motor UPDRS scores (Goetz et al 1999).
Reichmann et al conducted a study in 1202 PD patients 
who were switched slowly or quickly to pramipexole from 
any other oral DA, as add-on therapy, because of insufﬁ  cient 
effectiveness on motor performance, tremor, and mood 
(depression, anhedonia). The switch to pramipexole led to 
improvement of all symptoms. Resting tremor improved 
more than postural tremor. No difference was found between 
either switching procedure in respect to clinical efﬁ  cacy, 
tolerability, and safety. Most patients tolerated pramipexole 
better or equally well, compared with their previous DA 
(Reichmann et al 2006).
An analysis of 7 trials on pramipexole, ropinirole, 
pergolide, entacapone and tolcapone as add-on therapies 
to levodopa in PD found that pramipexole and entacapone 
were the best choices for obtaining a greater reduction in 
levodopa dose and in “off ” time, and a better tolerability. All 
active drugs caused about the same amount of dyskinesias 
except higher dose tolcapone (600 mg) which caused more 
dyskinesias (Inzelberg et al 2000).
In conclusion, most data suggest that pramipexole and 
the other DA are similarly efﬁ  cacious as adjuvant therapy 
to levodopa in advanced PD.
Speciﬁ  c symptoms
Drug-resistant tremor in Parkinson’s disease
Parkinsonian tremor can occasionally be unresponsive to 
dopaminergic therapy and notoriously difﬁ  cult to treat.
Navan et al conducted a randomized, double-blind, 
3-month parallel study in 30 PD patients, most of whom were 
already medicated. The aim was to investigate the effects of 
pramipexole, pergolide, and placebo on parkinsonian tremor. 
They found that both pergolide and pramipexole had sig-
niﬁ  cantly better overall antitremor effect than placebo, and 
their efﬁ  cacy was similar. However, pergolide was superior 
to pramipexole in alleviating rest tremor and postural tremor 
scored clinically. Both drugs had similar beneﬁ  cial effects on 
the UPDRS motor subscores and the tolerability was better 
for pramipexole (Navan et al 2003b). The same group did 
also report a similar but modest reduction in rest tremor with 
a single 500 µg dose of either pramipexole or pergolide, 
compared with placebo (Navan et al 2003a).
Pogarell et al investigated 84 early and advanced PD 
patients with marked drug-resistant tremor under a stable Neuropsychiatric Disease and Treatment 2008:4(2) 341
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and optimized antiparkinsonian medication. Pramipexole or 
placebo were administered as add on medication. The primary 
end point was the absolute change in tremor score, deﬁ  ned 
as the sum of UPDRS tremor related items (16, 20, 21) in 
“on” periods. Pramipexole was found to be signiﬁ  cantly 
superior to placebo with a difference between treatment 
groups in the mean absolute change in tremor score of –4.4 
points ([95% CI] –6.2 to –2.5; p  0.0001), corresponding 
to a difference in the mean percentage change of –34.7% in 
favor of pramipexole (Pogarell et al 2002).
In conclusion, existing data suggest that pramipexole may 
be effective for treating drug-resistant tremor in PD.
Non-motor symptoms in Parkinson’s disease
In addition to the noticeable motor symptoms, less obvious 
and sometimes more difﬁ  cult to treat non-motor symptoms 
may greatly increase the distress and disability in PD. Increas-
ing evidence supports pramipexole’s efﬁ  cacy in ameliorating 
some of these symptoms.
Depression: In non-PD patients with both unipolar and 
bipolar major depression, pramipexole was shown to be 
effective in alleviating depressive symptoms, in monotherapy 
or as an adjuvant (Corrigan et al 2000; Lattanzi et al 2002; 
Goldberg et al 2004). Depression and other psychiatric disor-
ders affect up to 50% of all PD patients (Dooneief et al 1992; 
Tandberg et al 1996) with negative impact on motor-related 
disability and quality of life (QOL) (Schrag et al 2000).
In a randomized trial from 2005 including 67 PD patients 
with major depression and without motor complications, 
pramipexole was compared with sertraline in respect to 
recovery from depression, defined as a final HAM-D 
(Hamilton 1960) score 8 (Lemke et al 2006). Pramipexole 
led to recovery in 60.6% of patients, which was signiﬁ  cantly 
higher compared with sertraline (27.3%). However, there was 
no difference between the two treatments when depression 
was assessed with Zung self-relating depression score (Zung 
1965). There were more adverse effects in the sertraline 
recipients, responsible for a 15% withdrawal from the study 
(5 patients). None of the 33 pramipexole patients withdrew. 
In the pramipexole group there was a signiﬁ  cant improve-
ment in motor symptoms as measured by UPDRS part III. A 
noticeable limitation of the study was the lack of a placebo 
group, given that there is a high degree of placebo response 
in depressed PD patients (Weintraub et al 2005).
A randomized, open-label, comparative study investi-
gated the effect of adjuvant therapy with pramipexole and 
pergolide in 41 non-demented, levodopa-treated PD patients, 
all of which had motor complications, including ﬂ  uctuations 
and dyskinesias. About a third of the patients in each DA 
group had mild to moderate depression at baseline. A sig-
niﬁ  cant decrease of Zung depression score (Zung 1965) was 
reported for both DA, but improvement on Montgomery-
Åsberg Depression Rating Scale (Montgomery and Asberg 
1979) was seen only among the pramipexole recipients. 
At the same time, pramipexole improved motor symptoms 
including motor complications, and this may also have been 
a cause for improved depression, although pramipexole was 
superior even when controlling for the motor improvement. 
There was no signiﬁ  cant difference between pramipexole 
and pergolide as adjuvant in respect to motor symptoms, 
activities of daily living, and treatment complications. The 
daily levodopa dose could be signiﬁ  cantly decreased, more 
so in the pergolide group (Rektorova et al 2003).
In conclusion, existing data suggest that pramipexole may 
play a role in reducing symptoms of depression in PD.
Anhedonia: An observational study on 657 PD patients 
in early and advanced disease stages (Hoehn and Yahr 1–5 
[Hoehn and Yahr 1967]) found that pramipexole as add-on to 
levodopa therapy improved anhedonia, the reduced capacity 
to experience pleasure, as evaluated by the Snaith-Hamilton 
Pleasure Scale (Snaith et al 1995). Notably, this was seen in 
both depressed and in non depressed PD patients, and was 
therefore not only due to an antidepressant effect. Meanwhile, 
in line with the results of other studies, it was seen that severe, 
moderate, and mild depression also decreased (Reichmann 
et al 2003; Lemke et al 2005; Lemke et al 2006).
Cognition: Cognitive impairment is common in PD, 
and up to a third of PD patients develop overt dementia 
(Aarsland et al 2005). As results from studies in healthy 
controls suggest that pramipexole may worsen cognitive 
abilities (Pizzagalli et al 2007), it is important to investigate 
its impact on cognition in PD.
Rektorová et al examined in a randomized study the 
effects of pramipexole and pergolide as adjuvant therapy 
to levodopa in 41 non-demented patients with advanced 
PD and a current depressive episode. While conﬁ  rming 
that pramipexole had an antidepressant effect and that both 
DA improved motor performance, the results showed no 
signiﬁ  cant effect on the neuropsychological tests applied. 
The conclusion was that both pramipexole and pergolide as 
adjuvant therapy to levodopa are safe in terms of effects on 
cognitive performance (Rektorova et al 2005).
Relja et al evaluated over 6 months the effects of 
pramipexole as add-on therapy in PD patients treated 
with levodopa. An exclusion criterion was evidence of 
possible dementia and only patients scoring above 25 on the Neuropsychiatric Disease and Treatment 2008:4(2) 342
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mini-mental state examination (MMSE) were included. They 
found no statistically signiﬁ  cant difference in performance 
on the cognitive tests applied, between those treated with 
levodopa in monotherapy and those adding pramipexole, 
but there was a trend for a greater decline on Letter Fluency 
(Benton 1989) and Trail Making test (Reitan 1992) in the 
latter group (Relja and Klepac 2006).
Brusa et al investigated in a randomized study 20 
patients with early/mild PD treated with levodopa or with 
pramipexole. Patients with dementia were excluded. They 
found that pramipexole but not levodopa produced a signiﬁ  cant 
impairment of short term verbal memory, attentional-executive 
functions, and verbal ﬂ  uency (Brusa et al 2003).
Given the fact that cognitive impairment is common in 
advanced PD, it would be of great interest to know more 
about pramipexole’s effects in a cognitively impaired 
PD population. In the previously mentioned studies, no 
demented PD subjects were included and no studies on 
pramipexole in a cognitively disabled PD population could 
be identiﬁ  ed. A case report regarding an 85 years old 
demented lady with parkinsonism indicated that pramipex-
ole might have contributed to a worsening of the patient’s 
cognition and general condition (Scoyni et al 2007). As 
cognitive decline is more common with advancing age 
and disease stage in PD, the results of one study on the 
use of DA in very elderly patients with PD are especially 
interesting in this context (Shulman et al 2000). In total, 
43 non-demented PD patients (24 between 80 and 85, 14 
between 86 and 90, and 5 between 91 and 95 years of age), 
with a mean disease duration of 11 years, were treated 
with pramipexole (mean daily dose 2.7 mg). The overall 
success rate over a mean treatment time of 14 months was 
40% (17 of 43 patients). The adverse effect event rate was 
of the same magnitude as in younger patients (around 60 
years old), and the adverse events proﬁ  le was similar with 
that reported in younger patients, with the exception of hal-
lucinations, which were more common in this very old age 
group. Thus 21% of the patients treated with pramipexole 
reported hallucinations. Unfortunately, the design of the 
study did not provide any speciﬁ  c data on cognition and 
the effects of pramipexole therapy.
Biglan et al found that better cognitive function deﬁ  ned 
as MMSE 28 was associated with a decreased risk for 
developing hallucinations after pramipexole therapy in PD 
(Biglan et al 2007).
In the light of the aforementioned results and especially 
considering the higher risk for hallucinations with prami-
pexole therapy, there is reason to suspect that pramipexole 
may have deleterious effects on cognition in an advanced 
PD population showing cognitive deﬁ  cits.
In conclusion, there are mixed results in respect to 
pramipexole’s impact on cognition in a non-demented PD 
population, with studies showing no deleterious effects and 
studies suggesting cognitive worsening. No studies suggest-
ing that pramipexole treatment may lead to an improvement 
in cognition were identiﬁ  ed. Although no studies examining 
the effects of pramipexole in a cognitively impaired PD 
population could be found, caution is recommended in this 
respect.
Apathy: Apathy is a frequent ﬁ  nding in PD, signiﬁ  cantly 
associated with cognitive impairment, executive dysfunction, 
anxiety and depression (Starkstein et al 1992; Aarsland et al 
1999; Pluck and Brown 2002). Apathy levels in PD are higher 
than in equally disabled patients with other diagnoses (Pluck 
and Brown 2002). While apathy does not seem to respond to 
levodopa, there are some indications from clinical trials that 
pramipexole’s D3 agonist properties may be beneﬁ  cial in this 
respect (Guttman and Jaskolka 2001; Kumru et al 2006).
Miscellaneous symptoms
Restless legs syndrome: There may be an overrepresentation 
of restless legs syndrome (RLS) in PD and the relationship 
between the two diseases is not completely elucidated (Poewe 
and Hogl 2004). Pramipexole has been shown to be effective 
in treating pure RLS (Montplaisir et al 1999), as well as other 
DA, but no studies investigating pramipexole’s efﬁ  cacy in the 
treatment of RLS in PD patients have been identiﬁ  ed.
Weight loss: Weight loss is seen in PD patients already 
before diagnosis and continues throughout the course of 
the disease. Possible causes include: (1) increased energy 
expenditure due to increased muscular activity (rigidity, 
dyskinesias); (2) decreased energy intake, due to general 
movement impairment (difﬁ  culties in feeding, accessing 
food, and swallowing), and decreased appetite caused by 
depression; and (3) an inherent metabolic abnormality in 
PD (Chen et al 2003; Lorefalt et al 2006; Toth et al 1997). 
Increased body weight, as well as motor and mood improve-
ment, were seen in 28 non-depressed, advanced PD patients 
on stable medication, 3 months after starting treatment with 
pramipexole (Kumru et al 2006). In addition, many patients 
treated with pramipexole reported a decrease in anxiety and 
apathy together with enhanced attention span and interest in 
daily activities. No patient reported dysphagia, vomiting or 
changes in eating behavior but 12 reported increased hunger. 
There was no relationship between changes in BMI and in 
UPDRS part III and the authors speculate that the weight Neuropsychiatric Disease and Treatment 2008:4(2) 343
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increase was due to a direct or indirect action of pramipexole 
on the feeding centers in the hypothalamus.
Rapid eye movement (REM) sleep behavior disorder 
(RBD): Rapid eye movement (REM) sleep behaviour disor-
der (RBD) may involve a dopaminergic deﬁ  ciency, as it is 
associated with both PD and RLS. The traditional ﬁ  rst-line 
therapy for RBD is clonazepam. Nevertheless, 2 studies were 
found that reported on pramipexole in RBD, although none 
was directed at PD patients.
Fantini et al reported about 8 patients with idiopathic 
RBD, treated with pramipexole, 7 of which experienced a 
reduction in the frequency and intensity of RBD. In 5 patients 
this reduction was sustained (Fantini et al 2003).
Schmidt et al reported about 10 patients with RBD, 3 of 
which had parkinsonism. Pramipexole reduced markedly 
the frequency and severity of RBD in 89% of the patients 
(Schmidt et al 2006).
The results of these studies are interesting but they have 
to be replicated in a PD population before gaining any accep-
tance in the treatment of PD related RBD.
Fatigue: Fatigue is an early symptom in some PD 
patients (Schiﬁ  tto 2006). While fatigue improved in patients 
with ﬁ  bromyalgia with pramipexole treatment (Holman 
and Myers 2005), it was reported as an adverse event in 
PD patients treated with pramipexole (Pinter et al 1999; 
Pogarell et al 2002).
Dopaminergic complications
in Parkinson’s disease
The risk of experiencing response ﬂ  uctuations (wearing 
off, on-off) or dyskinesias in PD has been evaluated at 
40% after about 5 years of levodopa treatment (Ahlskog 
and Muenter 2001).
The CALM-PD study examined the risk for developing 
dopaminergic complications in early PD individuals initially 
treated with pramipexole monotherapy versus levodopa 
monotherapy. Eventually all patients could add levodopa for 
emerging disability. After 2 years, 28 % of subjects assigned 
to pramipexole developed dopaminergic complications vs 
51% in the levodopa group (Parkinson Study Group 2000).
The 4-years results of the CALM-PD study showed that 
initial treatment with pramipexole vs initial treatment with 
levodopa resulted in a signiﬁ  cant reduction of the risk for 
developing dyskinesias (24.5% vs 54%), and wearing off 
(47% vs 62.7%), but in a higher risk for freezing (37.1% vs 
25.3%). The occurrence of disabling dyskinesias was uncom-
mon and did not differ between the two treatment groups. 
The risk for on-off ﬂ  uctuations was the same in both groups. 
Ten patients in the pramipexole group developed dyskinesias 
prior to the open-label levodopa treatment, 7 of which had 
never been exposed to levodopa (Parkinson Study Group 
2000; Holloway et al 2004). Initial pramipexole treatment 
was associated with the appearance of motor ﬂ  uctuations 
before dyskinesias (Hauser et al 2006).
A comparison of several published studies on the treat-
ment of early PD with levodopa, pramipexole, cabergoline, 
or ropinirole, showed a reduction in the risk for develop-
ing dyskinesias for all three DA compared with levodopa. 
This reduction was slightly higher for pramipexole and 
ropinirole compared with cabergoline (absolute risk reduc-
tions 20%, 25%, and 8% respectively). These ﬁ  ndings are 
not unexpected, as dyskinesias seem to be mediated by the 
D1 receptor, for which pramipexole has a very low afﬁ  n-
ity compared with other compounds, such as cabergoline 
(Inzelberg et al 2003).
Neuroprotection
In vitro and in vivo studies
Pramipexole has been shown to have several neuroprotective 
actions, presumably through its antiapoptotic, antioxidant, 
and antitoxic effects, and through induction of neurotrophic 
factors. In cell cultures pramipexole protected against dopa-
minergic neuronal death induced by glutamate (Izumi et al 
2007), 1-methyl-4-phenylpyridinium (MPP+) (Presgraves 
et al 2004), 6-hydroxydopamine (6-OHDA) (Le et al 
2000), rotenone (Gu et al 2004), L-dihydroxyphenylalanine 
(L-DOPA), and methamphetamine (Hall et al 1996); in a 
recent study, pramipexole was shown to prevent neurotoxicity 
induced by oligomers of beta-amyloid, suggesting that prami-
pexole may have a role to play also in the treatment of other 
neurodegenerative diseases related to beta-amyloid proteins 
(Uberti et al 2007); in a dopaminergic cell line, pramipexole 
attenuated neurotoxicity induced by dopamine and levodopa, 
possibly through a mechanism related to antioxidant activ-
ity, scavenging of free radicals such as hydrogen peroxide, 
and inhibition of apoptosis (Zou et al 1999). Pramipexole 
stimulated the production of a dopaminergic neurotrophic 
factor in tissue cultures (Carvey et al 2001), and increased 
the Nurr1 gene expression and protein levels (Pan et al 
2005). It has been hypothesized that by suppressing STN 
overactivity, pramipexole may ameliorate the subthalam-
icus nucleus mediated excitotoxicity. Finally, pramipexole 
reduced mitochondrial swelling and could thereby have an 
antiapoptotic effect (Cassarino et al 1998; Sayeed et al 2006). 
In mice, pramipexole treatment completely antagonized the 
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In humans
The CALM-PD study attempted to assess pramipexole’s 
neuroprotective effect in humans, by quantifying the rate of 
decline from baseline in striatal ([123]I)beta-CIT-SPECT 
uptake, a measure of the density of striatal presynaptic 
dopaminergic innervation, reﬂ  ecting the degeneration of 
substantia nigra. Forty-two PD subjects were randomized 
to initiate therapy with pramipexole and 40 with levodopa, 
both as monotherapy. Eventually, both groups could add 
levodopa when needed. After both 2 and 4 years of treatment, 
the group initially receiving pramipexole showed a slower 
rate of decline in striatal ([123]I)beta -CIT SPECT uptake 
compared with the group initially randomized to levodopa 
(7.1% vs 13.5% at 22 months (p = 0.004); and 16.0% vs 
25.5% at 46 months (p = 0.01). In addition, the percentage 
loss from baseline in striatal ([123]I)beta -CIT uptake was 
correlated with the change from baseline in UPDRS at the 
46-month evaluation (r = –0.40; p = 0.001) (Parkinson Study 
Group 2002). The interpretation of these results is equivocal 
due to the lack of a placebo group, and because it can not 
be ruled out that the differences in the rate of decline from 
baseline may be due to direct pharmacological effects of 
pramipexole on the ligand receptors, and not due to a slowing 
of the disease process with pramipexole (Ravina et al 2005). 
Both animal and human studies show for example that short 
term therapy with pramipexole can down-regulate striatal 
dopamine transporters (Guttman et al 2001).
The results of a subanalysis of CALM-PD data argue 
against a neuroprotective action of pramipexole, which, as 
initial therapy in PD, did not lower the risk for dyskinesias 
once levodopa was added to the treatment, after control-
ling for levodopa dose. Nonetheless, pramipexole delayed 
the point in time when levodopa treatment was needed 
and thereby delayed also the appearance of dyskinesias 
(Constantinescu et al 2007).
In conclusion, despite promising results in preclinical 
studies, there are still no convincing clinical data conﬁ  rming 




Using data from the CALM-PD study, Noyes et al made 
a cost-effectiveness assessment of initial treatment with 
pramipexole vs levodopa, in early PD. The results reﬂ  ect-
ing the ﬁ  rst 2 years of treatment suggested that pramipexole 
was not welfare enhancing due to higher costs compared 
with levodopa (Noyes et al 2004). However, after 4 years, 
the cost-effectiveness of pramipexole increased, with the 
largest incremental beneﬁ  t being noticed during the fourth 
year of the trial. The increased effectiveness was not due to 
a reduction in costs compared with levodopa, but to a greater 
gain in quality adjusted life years (QUALY). Subjects with 
lower QOL and more depressive symptoms at baseline 
showed the highest improvement in QUALY gains over time 
(Noyes et al 2005).
Quality of life (QOL)
Health-related QOL (HRQOL) evaluates a person’s well-
being. Several studies have shown that QOL decreases in 
PD patients as the disease progresses (Karlsen et al 2000). 
Data from the CALM-PD study was used to compare the 
effect of pramipexole vs levodopa on disease-speciﬁ  c QOL. 
Although at 24 months, the levodopa group showed better 
QOL scores than the pramipexole group (Parkinson Study 
Group, 2000), there was no difference in the mean changes 
in the HRQOL between baseline and 48 months follow up 
(Holloway et al 2004). However, this approach ignored the 
dynamics of HRQOL changes. Consequently, when taking 
into account the HRQOL values for all visits and accumu-
lating gains and losses over time, by each treatment arm, 
a different pattern emerged. During the ﬁ  rst year, HRQOL 
increased, and during years 2–4, it decreased in both arms. 
The deterioration was greater in the levodopa arm, although, 
at all times, there was a 5-point UPDRS beneﬁ  t favoring 
levodopa, suggesting that pramipexole induced its improve-
ment thorough non-motor and levodopa through motor 
mechanisms. The difference in HRQOL between the two 
treatment arms widened in years 3 and 4 in favor of prami-
pexole suggesting that a longer follow up may show even 
larger differences. The clinical relevance of these ﬁ  ndings 
is not clear at this time (Noyes et al 2006).
Tolerability and adverse events
As already discussed in section 3.3, pramipexole is gener-
ally well tolerated up to a total daily dose of 4.5 mg, both 
as monotherapy and as an adjuvant to levodopa in PD 
patients at different disease stages. The highest dosage of 
6 mg daily led to a higher incidence of neuropsychiatric 
side effects, particularly somnolence, and there is generally 
a direct relationship between pramipexole dose and adverse 
events. Adverse events that appear to occur more often with 
pramipexole compared with placebo are sleep disturbances, 
gastrointestinal symptoms (nausea, constipation), postural 
hypotension, peripheral edema, impulse control disorders, 
and hallucinosis (Lieberman et al 1997; Moller et al 2005; Neuropsychiatric Disease and Treatment 2008:4(2) 345
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Parkinson Study Group, 1997; Parkinson Study Group, 2000; 
Pinter et al 1999; Shannon et al 1997; Weiner et al 2001). 
The most alarming adverse events will be discussed in the 
following sections.
Increased somnolence and attacks
of sudden onset of sleep
Sleep disturbances such as excessive daytime sleepiness 
(somnolence) and disorders of night time sleep patterns are 
common in PD and contribute to a general deterioration of 
the QOL (Tandberg et al 1998). Intuitively, increased som-
nolence should also be related to potentially fatal attacks 
of sudden onset of sleep while driving. Indeed, 75% of 
PD patients reporting such attacks have high scores on the 
Epworth Sleepiness Scale (ESS) (Johns 1991). However, 
25% of the patients have low scores on ESS, suggesting that 
sleep attacks may be a sleep phenomenon not necessarily 
related to increased somnolence (Paus et al 2003). There 
are contradictory reports on the role of pramipexole in the 
development of somnolence and attacks of sudden onset of 
sleep, and, being a cause of great concern, this issue will be 
discussed at large in this review.
The initial report by Frucht et al from 1999, on 8 PD 
patients treated with pramipexole who experienced sudden, 
irresistible attacks of sleep, and sustained motor vehicle acci-
dents, led to a driving ban for pramipexole treated patients 
in some countries (Frucht et al 1999).
The following year Hauser et al reported data collected 
prior to Frucht’s report. Six of 22 (27%) PD patients ran-
domized to pramipexole reported somnolence, compared 
with only 2 of 18 (11%) placebo patients. In addition, 
during the open-label extension period, 21 of 37 (57%) 
patients receiving pramipexole reported somnolence as an 
adverse event, 7 (19%) reported falling asleep while driv-
ing, and 2 (5%) reported minor motor vehicle accidents. 
Sleep latency normalized after withdrawal of pramipexole 
(Hauser et al 2000).
The 4-year results of the CALM-PD study showed that 
more somnolence was reported in the pramipexole group 
at 4 years, and while only 1 subject (0.7%) in the levodopa 
group withdrew because of somnolence, 12 subjects (8%) in 
the pramipexole group did that. Of these, 8 subjects (66%) 
described their somnolence as “sudden” or “unexpected” and 
5 (41%) reported that these episodes occurred while driving. 
Two serious adverse events related to driving were reported 
in the levodopa group and 5 in the pramipexole group. Som-
nolence seemed to occur mostly during the escalation phase 
of pramipexole (Holloway et al 2004). A secondary analysis 
of this data found that initial treatment with pramipexole in 
patients with early PD almost doubled the risk for developing 
somnolence (Biglan et al 2007).
Etminan et al analyzed in two separate analyses the risk 
for somnolence in PD patients taking pramipexole and rop-
inirole vs placebo (4 trials) and patients taking these two DA 
as adjuvant therapy to levodopa (7 trials). They concluded 
that the risk for somnolence was higher with pramipexole or 
ropinirole both as monotherapy an as adjuvant to levodopa, 
compared with placebo or levodopa alone (Etminan et al 
2001). Pramipexole gave a lower risk for somnolence and 
hypotension compared to ropinirole, but a greater risk for 
hallucinations (Etminan et al 2003).
Happe et al found that sedation in PD may be a class effect 
of DA, with no difference between ergot and non-ergot DA 
(Happe and Berger, 2001).
O’Suilleabhain et al reported 2002 on 368 PD patients 
treated with levodopa and DA, in monotherapy or in combi-
nation therapy (O’Suilleabhain and Dewey 2002). One hun-
dred and seven patients took pramipexole. ESS was higher 
in PD as a group, compared with controls, and most of the 
increase could be accounted for by levodopa use, DA use, 
and PD severity. There was no signiﬁ  cant difference between 
the DA, when controlling for levodopa dose, but there was 
a trend toward higher total ESS for those using pramipexole 
(12.2) and pergolide (12.8) compared with ropinirole (10.6) 
or bromocriptine (8).
Hobson et al surveyed 638 PD patients, including 
420 drivers. Patients taking different DA and levodopa, 
in monotherapy or in combination, were compared with 
respect to attacks of sudden onset of sleep. Forty-nine driv-
ers (11.6%) reported such attacks. All medications and all 
combinations thereof could induce sudden onset of sleep, 
with the same risk in pramipexole users (13/143 or 9%) 
as in levodopa users (43/407 or 10.5%). No statistically 
signiﬁ  cant difference could be shown between the different 
DA, although the frequency of sudden sleep attacks was 
nominally highest in the ropinirole group (24/90 or 26%) 
(Hobson et al 2002).
In addition, in a review article from the same year, 
Homann and colleagues identiﬁ  ed 20 publications reporting 
sleep events in 124 PD patients, including 32 on pramipexole, 
84 on other DA, and 8 on levodopa monotherapy. Ninety six 
sleep attacks were identiﬁ  ed. Overall, 6.6% of PD patients 
taking DA reported sleep events (range 0%–30%), without 
any difference among the different medications, making sleep 
events a class effect of all dopaminergic drugs. The frequency 
of road accidents in PD patients was not higher than in age Neuropsychiatric Disease and Treatment 2008:4(2) 346
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matched controls, whether or not they were taking dopamine 
medication (Homann et al 2002).
Paus et al investigated 2592 PD patients, 284 of which 
were on a combination of pramipexole and levodopa therapy. 
Sudden sleep attacks were reported by 177 patients (6%) on 
phone interviews. The frequency of sleep attacks was low-
est for untreated PD patients (1.4%), higher for levodopa 
monotherapy (2.9%), DA monotherapy (5.3%), combination 
therapy levodopa plus one DA (7.3%), and it was highest for 
levodopa plus multiple DA therapy (9.2%). For pramipexole 
plus levodopa therapy, the frequency of sleep attacks without 
warning signs was 5.6% (95% CI 4.3–7.0). There was no 
signiﬁ  cant difference in this regard between pramipexole 
and the other DA (Paus et al 2003).
Similar results came from a study from 2005 on 929 
patients, 39% of which used pramipexole, 18.5% ropini-
role, 20% levodopa alone, and the rest a combination of 
different antiparkinsonian drugs. After controlling for all 
available patient characteristics, there was a signiﬁ  cant 
association between sudden uncontrollable somnolence 
and pramipexole therapy vs levodopa monotherapy (OR 
2.22. 95% CI 1.43–3.43). There was no signiﬁ  cant differ-
ence in this regard between the other DA tested (ropinirole, 
pergolide, bromocriptine) and pramipexole. There was also 
a dose-response relationship for pramipexole, with high 
doses resulting in a higher risk for somnolence, compared 
with small to medium doses (OR 2.79 vs 2.08 respectively) 
(Avorn et al 2005).
Romigi et al investigated one single PD patient with 
polysomnography. They found an increase in both the diurnal 
and the nocturnal sleep under pramipexole plus levodopa vs 
cabergoline plus levodopa therapy. The ESS scorings showed 
mild sleepiness on pramipexole and levodopa therapy, but 
were normal on cabergoline and levodopa and on levodopa 
alone. The patient did experience sleep episodes and irre-
sistible onset of daytime sleep, but no sleep attacks, and 
no sudden onset of daytime sleep, while on pramipexole 
and L-dopa therapy but not on other drug combinations. 
The authors conclude that there may exist an individual 
susceptibility to speciﬁ  c antiparkinsonian drugs with respect 
to sleepiness (Romigi et al 2005).
Razmy et al conducted a polysomnography study in PD 
patients treated with pramipexole, ropinirole, bromocriptine 
or pergolide, ﬁ  nding that the total dopaminergic drug dose 
given, rather than the speciﬁ  c DA used, was the best predictor 
of daytime sleepiness (Razmy et al 2004).
In conclusion, the available evidence shows that 
somnolence, while being part of PD itself, can be induced 
by all dopaminergic drugs, DA as well as levodopa itself. 
In addition, many other factors other than medication play 
an important role in this regard. Increased somnolence may 
be a risk factor for attacks with sudden onset of sleep, but 
sleep attacks can also occur without a prior increase in 
somnolence. The risk for increased somnolence is higher 
with DA, including pramipexole, compared with levodopa, 
but it seems to be similar in all DA, ergot, and non-ergot. 
Combination therapies increase the risk which is directly 
proportional with the total dose of dopaminergic equivalents. 
In the light of these ﬁ  ndings, disabling somnolence can be 
reduced with monotherapy, preferably with levodopa only, 
by reducing the total dopaminergic doses, by improving 
the night sleep, and by ﬁ  nding alternative therapies. In the 
particular patient, switch to another DA may be attempted, 
as the susceptibility to particular DA may differ between 
patients. Modaﬁ  nil treatment may be tried in difﬁ  cult cases 
although the evidence supporting the use of modaﬁ  nil in 
PD is conﬂ  icting (Nieves and Lang 2002; Adler et al 2003; 
Ondo et al 2005). Counseling is important for all patients 
treated with dopaminergic drugs, including pramipexole, 
and should include advice on night sleep hygiene, avoid-
ance of sedatives and alcohol, normalizing diurnal rhythms, 
pulling over to stop if a wave of sleepiness is perceived. PD 
patients should abstain altogether from driving and other 
activities which require intense alertness, when suffering 
from generalized drowsiness, and if falling asleep during 
inactivity, regardless of their antiparkinsonian medication 
(Holloway et al 2004).
Cardiac valvulopathy
The recent ﬁ  nding that pergolide and cabergoline can cause 
cardiac valvulopathies led to a wave or research pertaining 
to valvular abnormalities in patients treated with non-ergot 
DA as well.
Peralta et al investigated 75 PD patients and controls 
with echocardiography. Twenty-ﬁ  ve of the patients were 
treated with pramipexole. While the exposure to pergolide 
and cabergoline was associated with higher frequencies 
of valvular regurgitation compared to controls, that was 
not the case for the pramipexole treated patients, which 
showed about the same risk as controls, around 10% (Peralta 
et al 2006).
One study from Japan comprising 16 pramipexole treated 
PD patients found a higher frequency of insigniﬁ  cant forms of 
valvulopathy in the pramipexole group (25%) compared with 
the control group (17.6%), although the difference was not 
statistically signiﬁ  cant (OR 1.62 [0.45–5.87]). The authors Neuropsychiatric Disease and Treatment 2008:4(2) 347
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point out that a similar frequency of valvulopathy was found 
in a normal-population study (Yamamoto et al 2006).
Zanettini et al included in their study 36 PD patients 
treated with pramipexole, none of which showed any clinical 
important valvular regurgitation (Zanettini et al 2007).
Junghanns et al evaluated 85 PD patients treated with 
ergot and non-ergot DA (23 on pramipexole) together with 
38 age-matched controls. The frequencies of valvular heart 
disease were similar in the control group (37%) and the 
pramipexole group (26%) (Junghanns et al 2007).
In a large British case-study involving 11417 people 
who were prescribed drugs for PD, there were 31 patients 
with cardiac valve regurgitation, but none of them had been 
treated with pramipexole (Schade et al 2007).
Dewey et al included 21 pramipexole patients in their 
study comparing ergot (pergolide) and non-ergot DA (rop-
inirole and pramipexole) with respect to regurgitation. The 
conclusion was that the risk of cardiac valve regurgitation 
appeared to be low when using non – ergot-derived DA, much 
lower than for pergolide (Dewey et al 2007).
Thus, pramipexole does not seem to cause valvular abnor-
malities. These results are not unexpected as the cause of 
valvular ﬁ  brosis appears to be ﬁ  broblast activation mediated 
through the 5-HT2B serotonergic receptors (Rothman et al 
2000). While cabergoline and pergolide are strong agonists at 
this receptor, pramipexole’s afﬁ  nity for the 5-HT2B receptor 
is low, which explains its low risk for cardiac valvulopathy, 
comparable with that seen in controls.
Still, Chaudhuri et al reported in 2004 in a letter to the 
Editors of the journal Movement Disorders that they were 
“aware of pramipexole being implicated as well, at least in 
one case” in respect with “ﬁ  brotic reaction with non-ergot 
agonists” (Chaudhuri et al 2004). As no further information 
is provided, this remark adds nothing to this discussion, and 
may even be confusing. However, it is included here for the 
sake of comprehensiveness.
In conclusion, although the evidence concerning prami-
pexole and valvulopathy is reassuring so far, continued 
pharmacovigilance is advisable.
Impulse control disturbances
Recently, pramipexole and other DA have been reported to 
cause impulse control disorders (ICD) such as gambling, 
compulsive buying, and pathological hypersexuality.
Dodd et al investigated 11 PD patients who had devel-
oped pathological gambling and other behavioral disorders. 
Eighty-two percent of these were treated with pramipexole, 
discontinuation of which led to improvement. In a literature 
survey, the authors found 17 similar case reports, 10 (59%) 
of which were also treated with pramipexole, while the rest 
were taking other DA (Dodd et al 2005).
Klos et al reported on pathological hypersexuality in 13 
PD patients, 6 of which were treated with pramipexole, and 
in 2 multiple-system atrophy (MSA) patients, 1 of whom was 
treated with pramipexole (Klos et al 2005). Several of these 
patients had other obsessive-compulsive behaviors in addi-
tion to hypersexuality. The conditions resolved after stop-
ping pramipexole and/or adding antipsychotics. The authors 
identiﬁ  ed 14 additional cases in the literature, all treated with 
levodopa plus DA, although the agonists were others than 
pramipexole. They suggest that excessive stimulation of the 
D2 receptor class and speciﬁ  cally the D3 receptor subclass 
may have caused this behavior.
Weintraub et al investigated the prevalence of ICD in 
272 PD patients, half of which were treated with a DA 
(pramipexole, ropinirole, pergolide) (Weintraub et al 2006). 
Eighteen patients (6.6%) met criteria for ICD at some point 
during their disease course and all of these were taking a DA 
while symptomatic. Pramipexole was the most frequently 
prescribed DA, representing more than half of all DA use. 
There was no difference between the three agonists in respect 
to their association with ICD and the authors concluded that 
the risk associated with ICD was a class effect of the DA and 
not speciﬁ  c to a certain agonist. The main risk for developing 
ICD in the context of DA treatment was a history of ICD 
symptoms prior to PD. A long term follow-up of 15 of these 
patients (mean time period 29 months) showed that 80% of 
them had discontinued or signiﬁ  cantly reduced the DA treat-
ment, and all these patients went into full or partial remission. 
However, most of these patients had increased the levodopa 
dosage, and the total levodopa equivalent daily dosage, as 
well as the UPDRS motor score, were similar at follow up. Of 
the three patients who had the same DA treatment at follow 
up, one was taking pramipexole. His compulsive sexuality 
had gone into full remission after DBS surgery and decreased 
amantadine dose (Mamikonyan et al 2008).
There is one case report of pathological gambling associ-
ated with pramipexole in a patient with restless legs syndrome 
(Quickfall and Suchowersky 2007).
In conclusion, according to several reports, there is a 
signiﬁ  cant risk for developing ICD in patients treated with 
pramipexole and other DA. This risk seems to be a class effect 
and is not speciﬁ  c to pramipexole alone. In North America 
and also in many European countries, pramipexole is the 
most used DA, implying that more patients are exposed to 
it compared with the other agonists. This may lead to more Neuropsychiatric Disease and Treatment 2008:4(2) 348
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reports on gambling and other behavioral disorders during 
pramipexole treatment, although the risk may be the same 
with other DA (Lu et al 2006).
Hallucinations
In studies on early PD, hallucinations occurred in 9% of 
pramipexole-treated patients, compared with 2.6% of patients 
on placebo. The same pattern was seen in advanced PD, with 
almost 17% of pramipexole treated patients developing hal-
lucinations, compared with 3.8% in the placebo group. The 
development of hallucinations was one of the most common 
causes of study termination in patients with advanced PD 
(2.7% on pramipexole vs 0.4% on placebo) (Pinter et al 
1999; Shannon et al 1997; Parkinson Study Group 2000; 
Mizuno et al 2003; Moller et al 2005). A meta-analysis found 
that, compared with placebo, pramipexole was associated 
with a higher risk for hallucinations than ropinirole (RR 5.2 
[1.97–13.72] vs 2.75 [0.55–13.73]) (Etminan et al 2003).
The 4-year results of the CALM-PD study showed that 
while hallucinations were reported to be more common in the 
pramipexole group vs the levodopa group after 2 years, there 
was no signiﬁ  cant difference at 4 years (Parkinson Study 
Group 2000; Holloway et al 2004; ). The risk for develop-
ing hallucinations was higher in younger patients initially 
treated with pramipexole, compared with younger patients 
initially treated with levodopa, but this was not seen in the 
older cohort. Cognitive disturbances, older age and greater 
comorbid illness were associated with more hallucinations 
(Biglan et al 2007).
In conclusion, there is an increased risk for hallucinations 
in PD patients treated with pramipexole.
Edema
Edema is a known adverse event associated with pramipexole 
treatment (Shannon et al 1997).
Tan and Ondo reported on 15 PD patients and 2 RLS 
patients who developed pedal edema, out of 300 patients 
treated with pramipexole. Edema abated after pramipexole 
discontinuation but it returned with reintroduction of prami-
pexole. Its intensity was dose dependent. No predisposing 
factors could be identiﬁ  ed (Tan and Ondo 2000).
The 4-year results of the CALM-PD study showed that 
edema and cellulitis were later phenomena, reported more 
often in the pramipexole group. Five patients (3.3%) in the 
pramipexole group withdrew because of edema, but none in 
the levodopa group (Holloway et al 2004).
In a retrospective medical record review, Kleiner-
Fisman et al found a 7.7% (95% CI, 4.5%–12.9%) risk for 
development of pedal edema in the ﬁ  rst year after initiation 
of pramipexole therapy in 237 PD patients, with more rapid 
development of edema among those with a history of coro-
nary artery disease. In total, 16% of all patients developed 
pedal edema, about the same prevalence as reported from the 
CALM-PD study (14.6%) (Parkinson Study Group 2000). 
There was no relationship between dose of pramipexole 
and incidence and severity of pedal edema, and the edema 
resolved with withdrawal of pramipexole in 71% of cases 
(Kleiner-Fisman and Fisman 2007).
In a secondary analysis of the CALM-PD trial, Biglan 
et al showed that initial pramipexole treatment in patients 
with early PD therapy was associated with development of 
edema (HR 3.18, 95% CI 1.95–5.18, p  0.0001), together 
with female gender and comorbid cardiac disease. Edema 
occurred mostly after 2 years of treatment, and not initially, 
which may explain why previous studies did not report edema 
as a common complication (Biglan et al 2007).
In conclusion, pedal edema is a relatively common 
outcome in patients with PD receiving pramipexole, with a 
higher risk in patients with a history of cardiac disease.
Conclusion: Pramipexole’s place in
the therapy of Parkinson’s disease
Pramipexole is generally well tolerated and efﬁ  cacious in 
treating motor symptoms in both early and advanced PD. Its 
efﬁ  cacy and tolerability are similar in African Americans, 
Asians, Caucasians and Hispanics. As initial treatment it 
may delay the onset of dyskinesias by delaying the start of 
levodopa therapy. It appears to have beneﬁ  cial effects on 
non-motor symptoms such as depression, and it may improve 
treatment-resistant tremor, anhedonia and weight loss. Prami-
pexole seems to have neuroprotective effects in vitro and in 
animal models but these ﬁ  ndings have not been replicated in 
humans. Compared with levodopa treatment, pramipexole 
therapy is associated with a higher risk for developing hal-
lucinations, somnolence (and indirectly attacks of sudden 
onset of sleep), impulse control disturbances, peripheral 
edema, but not cardiac valvular disease. The risk for adverse 
events increases with patient age, pramipexole dose, severity 
of PD, concomitant combination therapy, and comorbidity, 
especially cardio-vascular. Continued pharmacovigilance in 
respect to adverse events, especially increased somnolence, 
cardiac valvulopathy, and psychiatric effects is necessary. 
Although pramipexole therapy is more costly than levodopa, 
the cost effectiveness increases over time due to a higher gain 
in QoL. More research is needed regarding pramipexole’s 
neuroprotective potential and its impact on cognition, apathy, Neuropsychiatric Disease and Treatment 2008:4(2) 349
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fatigue, QoL, and treatment costs in PD. Pramipexole seems 
especially well suited for younger PD patients (65 years), 
without cognitive disturbances, with low comorbidity, at 
high risk for developing dyskinesias, and with particular PD 
features shown to be responsive to pramipexole.
Limitations
The literature search was limited to Medline. Although a lot 
of effort was made for identifying all publications related to 
every topic, there is always the risk that some publications 
have not been found. No publication judged to be relevant 
for this topic has been deliberately omitted. Table 1 offers a 
summary of the most important studies used for this review. 
No government agencies monitoring adverse events or 
pharmaceutical companies were contacted. This may bias 
the selection of publications.
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